Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's Syndrome

NCT05269810 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sjögren's Syndrome (pSS)

Interventions

DRUG: SA001 Low dose
DRUG: SA001 Mid dose
DRUG: SA001 High dose
DRUG: Placebo

Sponsor

Samjin Pharmaceutical Co., Ltd.